Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

VHL anticorps

VHL Reactivité: Humain, Souris, Rat IHC, IF Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7254899
  • Antigène Voir toutes VHL Anticorps
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Reactivité
    • 61
    • 37
    • 34
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain, Souris, Rat
    Hôte
    • 64
    • 13
    • 2
    Lapin
    Clonalité
    • 69
    • 10
    Polyclonal
    Conjugué
    • 41
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Cet anticorp VHL est non-conjugé
    Application
    • 47
    • 27
    • 26
    • 26
    • 19
    • 16
    • 12
    • 8
    • 6
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Immunohistochemistry (IHC), Immunofluorescence (IF)
    Attributs du produit
    Polyclonal Antibody
    Purification
    Affinity purification
    Immunogène
    Recombinant fusion protein of human VHL (NP_937799.1).
    Isotype
    IgG
    Top Product
    Discover our top product VHL Anticorps primaire
  • Indications d'application
    IHC 1:50-1:200 IF 1:50-1:200
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C
    Stockage commentaire
    Store at -20°C. Avoid freeze / thaw cycles.
  • Antigène
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Autre désignation
    VHL (VHL Produits)
    Synonymes
    anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992
    Sujet
    Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
    ID gène
    7428
    UniProt
    P40337
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
Vous êtes ici:
Support technique